Oral Complications from Oropharyngeal Cancer Therapy

Cancers, Journal Year: 2023, Volume and Issue: 15(18), P. 4548 - 4548

Published: Sept. 14, 2023

Post-oropharyngeal cancer treatment complications include a multitude of oral side effects that impact overall survival and quality life. These acute chronic conditions affecting the cavity head neck, such as mucositis, infection, xerostomia, dysgeusia, radiation caries, osteonecrosis, trismus. This review will summarize most common from oropharyngeal therapy. The authors would like to point out literature cited frequently combines neck results. If recommendations are made strictly related cancers, this be highlighted.

Language: Английский

---

Avasopasem for the treatment of radiotherapy-induced severe oral mucositis

Expert Opinion on Investigational Drugs, Journal Year: 2023, Volume and Issue: 32(6), P. 463 - 470

Published: June 3, 2023

ABSTRACTIntroduction Oral mucositis (OM) remains a significant, highly symptomatic, disruptive side effect of radiation and concomitant chemoradiation therapy used for the treatment squamous cell cancers head neck. Despite its clinical economic burden, implementation an effective intervention has been elusive.Areas covered Increased understanding complexity biological basis pathogenesis yielded potential druggable targets such as mitigation superoxide formation oxidative stress. Avasopasem manganese is selective dismutase mimetic being developed by Galera Therapeutics, which recently submitted New Drug Application (NDA) to FDA severe OM indication. This review describes preclinical studies led to, supported NDA, assesses utility avasopasem clinically.Expert opinion appears effectively mitigate associated with in neck cancers, well cisplatin-associated renal toxicity absence impairing tumor response.KEYWORDS: mucositisradiationchemoradiationhead canceravasopasem manganeseclinical development Article highlights common, treatment-limiting standard regimens neck.Oxidative stress critical component initiation events precipitate development.Avasopasem manganese, mimetic, supplement naturally occurring antioxidant mechanism favorably protect normal oral mucosa while not interfering radiosensitivity.Pre-clinical data have consistently indicated that safe mitigating course incidence regimens.The requirement intravenous administration proximity could require infrastructure changes high volume practices and/or coordination between radiotherapy sites infusion centers.Avasopasem be positioned breakthrough otherwise unmanageable complication therapy.Declaration interestDr Sonis employee Biomodels, LLC Primary Endpoint Solutions, LLC. Both companies assist industry, government, academics study enable drugs, biologicals, devices treat patients variety indications including cancer effects toxicities treatment. done contract work Galera. Dr does equity any either organization works.The authors no other relevant affiliations or financial involvement entity interest conflict subject matter materials discussed manuscript apart from those disclosed.Reviewer disclosuresPeer reviewers on this relationships disclose.AcknowledgmentsWe thank Robert Beardsley providing historical background manganese.Additional informationFundingThis paper was funded.

Language: Английский

---

Taste dysfunction symptoms experience in head and neck cancer patients undergoing proton and heavy ion therapy: a qualitative study

Supportive Care in Cancer, Journal Year: 2024, Volume and Issue: 33(1)

Published: Dec. 11, 2024

Language: Английский

---

Toxicity with proton therapy for oral and/or oropharyngeal cancers

Journal of Oral Pathology and Medicine, Journal Year: 2023, Volume and Issue: 52(5), P. 456 - 457

Published: March 24, 2023

The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/jop.13431. letter to the editor does not contain original data from Erkan Topkan, Busra Yilmaz, Efsun Somay, and Ugur Selek. Therefore, availability statement applicable.

Language: Английский

---